

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Surgery

**ESPS manuscript NO:** 22875

**Title:** Targeted therapy of gastrointestinal stromal tumours

**Reviewer's code:** 00742250

**Reviewer's country:** Japan

**Science editor:** Shui Qiu

**Date sent for review:** 2015-10-02 15:23

**Date reviewed:** 2015-10-03 07:02

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[ Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[ Y] No	

## COMMENTS TO AUTHORS

This is a good review article. There is no parts to be revised in the text, but Second table has a misspelling, Table 2 is correct.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Surgery

**ESPS manuscript NO:** 22875

**Title:** Targeted therapy of gastrointestinal stromal tumours

**Reviewer's code:** 00066723

**Reviewer's country:** Netherlands

**Science editor:** Shui Qiu

**Date sent for review:** 2015-10-02 15:23

**Date reviewed:** 2015-10-06 04:47

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Duplicate publication	publication
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	language polishing	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

The manuscript gives an overview of the use of tyrosine kinase inhibitors for the treatment of gastrointestinal stromal tumors. The manuscript is interesting for those who quickly want to learn how GIST is treated nowadays. However, some comments should be addressed before this manuscript can be considered for publication. Major comments 1. In the abstract the authors mention small GIST lesions with a benign behavior. However, these so called micro-GISTS are not mentioned in the main text. Please include a paragraph on these lesions. 2. Page 4, line 15 - "...induced partial response in 53.7% and led to stable disease in 27.9% of patients." Please correct text. 3. Page 9, line 22 - 24 - Can a dose increase from 400 mg to 800 mg /day really overcome resistance if a patient developed "secondary" mutations? 4. Page 10 - When discussing the potential use of ponatinib also refer to Garner AP et al (2014) Clin. Cancer Res. 20: 5745- 5. Please note that multiple references are in fact duplicated in the reference list e.g. Refs 3 and 4 are the same; Refs 5 and 9 are the same; Refs 8 and 10 are the same; Refs 19 and 23 are the same; Refs 20 and 22 are the same; Refs 30 and 47 are the same; Refs 34 and 48 are the same. Furthermore referring to Clinical Cancer Research as "Clin Cancer Res Off J Am Assoc Cancer Res" is extremely confusing. Similar the

reference to Journal of Clinical Oncology. Please carefully check references and correct. Minor comments 1. Please number the pages. 2. Carefully proofread the manuscript paying special attention to the english grammar and wording. 3. Page 3, final line - "...which have mutations acting on downstream of receptor kinases...." Please rephrase this sentence as it is unclear and give examples which genes are mutated in wild-type GIST. 4. Page 4, line 8 - This is the first use of RCT, please explain this abbreviation here. 5. Page 4, line 22 - What is meant with: "Grade 3 or 4 toxicities were approximately 21% patients". Words have been omitted, please correct. 6. Page 5, line 19, 20 - What is meant by "wild-type mutation"? Please explain. 7. Page 6, line 9 -10 - "...similarly PFS was significantly better PFS ....." Unclear what the authors try to convey. Please rephrase. 8. Page 8. Line 30 - NCCN, please explain abbreviation. 9. Table 2 is mistakenly labelled Table 1.